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Purpose. To describe a patient with two episodes of deep venous thrombosis and factor V Leiden mutation who presented with
central retinal vein occlusion (CRVO) despite prophylactic use of warfarin sodium (Coumadin). Methods.Ac a s er e p o r to fa
44-year-old woman with a history of recurrent deep venous thrombosis and Factor V Leiden mutation was placed on lifelong
prophylactic therapy with warfarin. The patient presented with CRVO in the left eye despite therapeutic levels of warfarin. Results.
Extensive systemic evaluation disclosed high titers for antinuclear antibody (ANA). Conclusion. Systemic anticoagulation with
warfarinmaynotprecludefurtherthromboticepisodes.Inyoungerpatientspresentingwithretinalveinocclusionandpre-existing
multiple thrombophilic risk factors, a multidisciplinary approach is recommended to explore other therapeutic options to avoid
further thromboembolic complications.
Copyright © 2009 Sarwat Salim et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Vascular occlusive disease of the retina has various etiologies.
In the older population, systemic vascular diseases such as
diabetes and hypertension are common. In younger patients,
inherited coagulation abnormalities are usually responsible
[1]. We report a case of a young woman who presented with
CRVO due to a hypercoagulable state secondary to factor V
Leiden mutation, despite systemic anticoagulation therapy.
2.CaseDescription
A 44-year-old woman with a history of recurrent deep
venous thrombosis was started on lifelong warfarin therapy
after being diagnosed with factor V Leiden mutation. Three
years later, she presented with acute visual loss in the left
eye. Examination revealed visual acuity of 20/30 OD and
5/200 OS. Slit lamp examination was unremarkable. Fundus
examination of the right eye was normal and in the left eye,
retinal hemorrhages and dilated retinal veins were present in
all four quadrants along with macular edema.
Systemic evaluation disclosed normal serum electrolytes
and blood cell count. The INR was reported to be in
therapeuticrange,2.48.Anticardiolipinantibodiesandlupus
anticoagulants were negative but high titers of ANA were
documented (1 : 320 with speckled pattern). The rheuma-
tology service decided to monitor the patient closely for
development of systemic lupus erythematosis (SLE) given
high titers of ANA.
3. Comment
Factor V Leiden mutation is known to be the most common
cause of inherited thrombophilia and has been shown to be a
causative factor in CRVO [1]. This point mutation involving
an amino acid substitution, where arginine is converted to
glutamine at position 506, results in resistance to activated
protein C, a protease that plays a vital role in physiological
anticoagulation by inactivating the coagulant factors V and
VIII.
Thromboembolic complications are frequently observed
in patients with SLE, and the risk of thrombosis is further
potentiated in the presence of Factor V Leiden mutation [2].2 Case Reports in Medicine
Patients with SLE, even in the absence of antiphospholipid
antibodies, carry a six fold risk of venous thromboembolism
when compared to the general population.
Browning and Fraser [3]r e p o r t e do c c u r r e n c eo fC R V O
in eyes despite the use of systemic warfarin; however,
the majority of their patients had low INRs relative to
the indication for anticoagulation (INR < 2). In contrast,
Mruthyunjaya et al. [4]r e p o r t e do c c u r r e n c eo fC R V Ow i t h
variable INR values, concluding that therapeutic range of
INR is important to prevent secondary systemic thrombotic
and embolic disease. Our patient developed CRVO despite
the recommended therapeutic level of warfarin.
Management of young patients with multiple throm-
bophilic risk factors continues to be a tremendous challenge
for clinicians. Although the use of concomitant anticoagula-
tion and antiplatelet therapy (aspirin, clopidogrel) remains
controversial, some have suggested a higher INR with anti-
coagulation and/or addition of antiplatelet therapy to avoid
further thromboembolic morbidity and mortality. The use
of various classes of medications with diﬀerent mechanism
of action may provide some beneﬁt; however, additional
studies are needed to substantiate these recommendations
[5]. One needs to be mindful of increased risk of bleeding,
and therefore, the need for a combination therapy must
be individualized using a multidisciplinary approach with
various subspecialists, including hematologists.
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